India`s Concord Biotech up 23% in debut, valuing it at over $1 billion
![](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/08/8c0a71ca5e740b55668ba1d972723186.jpg)
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Shares of Indian biopharma company Concord Biotech climbed as much as 23.7% in their market debut on Friday, valuing it at 95.92 billion rupees ($1.15 billion).
The company, which makes active pharmaceutical ingredients, the key biologically active elements in a drug, opened at 900.05 rupees compared with its initial public offer (IPO) price of 741 rupees.
Indian benchmark indexes, the Nifty 50 and the S&P BSE Sensex, were down 0.5% each as of 10:02 a.m. IST.
($1 = 83.0800 Indian rupees)
![](https://portfolio.investmentguruindia.com/uploads/news/insurance 123.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Axis Securities Ltd.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Wipro.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/2b1715f7e03b51b0ac9c014eb224fc1f.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/gdp22.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Geojit Financial Services.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Dollar retures 2.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/health22.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Arvind Kapil, MD and CEO, Poonawalla Fincorp.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/stock8.jpg)